Ipsen shares decline 3.5% and mark the worst performer on the SBF 120
The Parisian biopharmaceutical laboratory experienced its worst session of the index on Tuesday morning, driven by a surprise downgrade from Barclays which simultaneously lowered its rating and price target. The decline occurs in a moderately bearish Parisian market, without amplifying the overall trend.
Barclays downgrades Ipsen and lowers price target below previous closing price
Barclays revised its opinion on Ipsen on Tuesday, moving from "market weight" to "underweight" while lowering its price target from €170 to €155. This new target level is below the current price of €158.20, which implies, according to this analyst opinion, a potential for further decline of approximately 2% compared to current session levels. The stock retreated 3.42% and emerged as the strongest decline on the SBF 120, in an index that itself fell 0.37% during the session. This decline follows two similar episodes in August and early September: a decline of nearly 3% in late August after a failure under resistance, then another sell-off of nearly 3% on September 4th, so that the accumulated correction over the week now reaches 3% and the monthly decline exceeds 2%.
The price drops below its short-term moving averages, but the 200-day MA still provides a cushion
At €158.20, the stock is trading below its 20-day MA at €162.68 and its 50-day MA at €162.73, two nearly overlapping levels that now form an intermediate resistance. The gap from these two averages is approximately 2.75%, marking a breakdown of the dynamic support zone that had contained previous declines. Conversely, the 200-day MA at €151.44, well below the current price (gap of 4.46%), still provides a comfortable cushion before the static support level identified at €153.10.
The RSI at 51 remains neutral, without oversold signals despite the magnitude of today's decline, leaving the configuration open to both scenarios. In this context, the resistance from the moving averages at €162.70 is the next level to break for a reversal, while the support at €153.10 constitutes the floor to monitor in case of further decline.
